GlassScriptPhysician profile
Alexandria D Johnson
NPI 1114351202
$5,568.15
in general payments reported to CMS, 2019-2025
31 companies · $1,317 in 2025
The $1,317 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $100 · 2022: $1,792 · 2023: $926 · 2024: $1,433 · 2025: $1,317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,676.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,675.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,450.31 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $667.58 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Koya Medical, INC. | $585.84 | 2022 | |
| Shield Therapeutics INC | $459.35 | 2024-2025 | |
| Novo Nordisk INC | $445.39 | 2022-2025 | Ozempic, Rybelsus |
| Amgen INC. | $315.22 | 2022-2025 | Otezla, Repatha, Evenity |
| Exact Sciences Corporation | $255.11 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $179.56 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $138.71 | 2022-2023 | Verquvo, Belsomra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $131.13 | 2022-2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $116.48 | 2022-2024 | Eliquis |
| Pfizer INC. | $99.52 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $74.82 | 2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $73.28 | 2022-2023 | |
| Glaxosmithkline, LLC. | $72.93 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $69.63 | 2023-2025 | Keveyis, Gvoke Hypopen |
| Lilly USA, LLC | $60.69 | 2022 | |
| Janssen Pharmaceuticals, INC | $46.69 | 2021-2022 | |
| Dexcom, INC. | $42.07 | 2024 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $32.73 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $30.98 | 2024 | Nuedexta |
| Kowa Pharmaceuticals America, INC. | $30.83 | 2022 | |
| Viatris Specialty LLC | $30.39 | 2025 | Yupelri |
| Organon LLC | $28.56 | 2022-2023 | Nexplanon |
| Verona Pharma, INC. | $24.73 | 2025 | Ohtuvayre |
| Sanofi-Aventis U.S. LLC | $23.74 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.53 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $17.19 | 2021 | |
| Mylan Specialty L.P. | $16.53 | 2023 | Yupelri |
| Amarin Pharma, INC. | $13.19 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandria Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.